The benefits of active vitamin D analogs for reducing serum PTH levels are counterweighted by the risk of rising serum calcium levels and subsequently calcium-phosphate product, eventually leading to extraskeletal calcifications and worsening of cardiovascular disease. This evidence concerns the gene PTH and cardiovascular disorder.